Regulation | Ophthalmology Innovation Source

OIS Overview: Haimovitch, Lachman Share Insights On OIS, MIGs, IOLs, etc

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 040″] Veteran Ophthalmology Scribes Larry Haimovitch of Haimovitch Medical Technology Consultants and Mike Lachman of EyeQ Research put down the pens and pick up the Mics to share their insights on ophthalmology.

Lifitegrast Heads Up Promising Dry Eye Pipeline

For more than a decade, there has only been one approved pharmacologic treatment for dry eye—Allergan’s Restasis (topical cyclosporine 0.05%). This in a market estimated to be worth more than $2.4 billion, one that affects up to 100 million people worldwide, and one that is expected to grow by almost 3% yearly. Dry eye products…

Alphaeon’s Grant Explains Innovative New Model

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 034″] Alphaeon is tapping physicians for unprecedented involvement in finding and funding new treatments. Hear how the company sees the future of health care.

How to Do M&A Well

Highlights of a discussion between the ophthalmology sector’s top execs about how to do M&A right. Moderator: Jim Mazzo Jim Mazzo is the Executive Chairman and CEO for AcuFocus. AcuFocus specializes in presbyopia correction and is known for its revolutionary KAMRA inlay which was recently FDA approved. View Full Profile Panelists: Jeff George Jeff was…

IOPtima

Ronen Castro, CEO of Israeli company IOPtima Ltd., introduced the CLASS (CO2 Laser-Assisted Sclerectomy Surgery) procedure for glaucoma, which has results comparable to trabeculectomy, but is non-invasive. This was the company’s first year for commercial activity. In March it secured CFDA approval in China, and in the fourth quarter of this year it begins initial…

Alcon’s Head Jeff George Lays Out Vision

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 015″] Jeff George, President & Global Head of Alcon, shares his optimism for the ophthalmology sector with attendees at the recent Ophthalmology Innovation Summit in Chicago. George explained where Alcon was putting research and development dollars (spoiler, one involves Google.) He also identified what he saw as intriguing companies and technologies…

Anido Guides Aerie’s Push To Be A “Very Big Player” In Glaucoma

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 009″] Vicente Anido, Jr., PhD’s career has taken him through large companies and private start-ups. He’s taken life science companies public on two occasions, and he’s seen nearly every perspective of the ophthalmology industry. Today, Anido expects big things for Aerie Pharmaceuticals, a clinical-stage pharmaceutical company with two promising treatments for…

Ophthalmology Leaders Speak to Strength of Sector

A Wall Street Journal analysis of venture capital commitments showed ophthalmology remained the strongest sector within healthcare. According to the Wall Street Journal, privately held ophthalmology start-ups drew $442.7 million in capital over the first six months of this year, putting it on pace to surpass the $848.9 million raised in 2013. With the baby…

The Role of OUS Clinical Studies

Malvina B. Eydelman, MD give her presentation on some of the newest directions coming out of the FDA for device studies in the US followed by a panel discussion on clinical studies in the US vs. clinical studies overseas. Moderator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest…

Cross Linking Market Overview

Presenter: Stephen Slade, MD Stephen Glenn Slade graduated from the University of Texas (Summa Cum Laude, Phi Beta Kappa) with a final, elective year spent at Guy’s Hospital in London. He completed a residency at LSU in New Orleans and fellowships at Baylor College of Medicine and Project ORBIS in New York. View Full Profile

Neovista – A Challenging Journey

Versant Ventures Managing Director William J. Link PhD talks about the journey of NeoVista through all of its ups and downs. Ultimately Neovista was able to get its CE Mark, but failed to get approved by the FDA due to a spiral of “stacking” risks. Presenter: William J. Link, PhD Bill was Founder, Chairman and…

Cross Linking – Panel Discussion

Moderators: Stephen Slade, MD Stephen Glenn Slade graduated from the University of Texas (Summa Cum Laude, Phi Beta Kappa) with a final, elective year spent at Guy’s Hospital in London. He completed a residency at LSU in New Orleans and fellowships at Baylor College of Medicine and Project ORBIS in New York. View Full Profile…